Your browser doesn't support javascript.
loading
Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost-Utility and Budget Impact Analysis.
Imaz-Iglesia, Iñaki; Carmona, Montserrat; García-Carpintero, Esther E; Pedrosa-Pérez, Lucía; Martínez-Portillo, Alejandro; Alcalde-Cabero, Enrique; Linertová, Renata; García-Pérez, Lidia.
Afiliación
  • Imaz-Iglesia I; National Health School, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.
  • Carmona M; Chronicity, Primary Healthcare and Health Promotion Research Network (Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud/RICAPPS), 28029 Madrid, Spain.
  • García-Carpintero EE; Chronicity, Primary Healthcare and Health Promotion Research Network (Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud/RICAPPS), 28029 Madrid, Spain.
  • Pedrosa-Pérez L; Health Technology Assessment Agency, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.
  • Martínez-Portillo A; Chronicity, Primary Healthcare and Health Promotion Research Network (Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud/RICAPPS), 28029 Madrid, Spain.
  • Alcalde-Cabero E; Health Technology Assessment Agency, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.
  • Linertová R; Health Technology Assessment Agency, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.
  • García-Pérez L; National Health School, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.
Viruses ; 16(8)2024 Jul 25.
Article en En | MEDLINE | ID: mdl-39205168
ABSTRACT
Two vaccines against rotavirus diseases, Rotarix® and RotaTeq®, are being marketed in Spain; but rotavirus is not presently among the diseases covered by universal vaccination in Spain. The aim of this study was to assess the efficiency of extending Spain's current targeted rotavirus vaccination strategy including only preterm babies, to a policy of universal vaccination. A de novo cohort-based Markov model was built to evaluate the efficiency of three compared rotavirus vaccination strategies in Spain targeted, universal, and no vaccination. Using Rotarix® or RotaTeq®, we compared the cost-utility of these strategies from both a societal perspective and Spanish National Health System (SNHS) perspective. The model represents the most important clinical events conceivably linked to rotavirus infection. Efficacy, effectiveness, safety, costs, and utilities were identified by systematic reviews. Incremental cost-utility ratio (ICUR) is EUR 23,638/QALY (Quality-Adjusted Life Year) for targeted vaccination with Rotarix® compared with no vaccination. The ICUR for the rest of the strategies evaluated are above EUR 30,000/QALY. The sensitivity analysis shows price as the only parameter that could make the universal vaccination strategy efficient. Considering a threshold of EUR 25,000/QALY, only targeted vaccination with Rotarix® would be efficient from societal perspective. Price drops of 36.9% for Rotarix® and 44.6% for RotaTeq® would make universal vaccination efficient.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Rotavirus / Vacunas Atenuadas / Vacunación / Análisis Costo-Beneficio / Años de Vida Ajustados por Calidad de Vida / Vacunas contra Rotavirus Límite: Child, preschool / Humans / Infant / Newborn País/Región como asunto: Europa Idioma: En Revista: Viruses Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Rotavirus / Vacunas Atenuadas / Vacunación / Análisis Costo-Beneficio / Años de Vida Ajustados por Calidad de Vida / Vacunas contra Rotavirus Límite: Child, preschool / Humans / Infant / Newborn País/Región como asunto: Europa Idioma: En Revista: Viruses Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza